KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aurinia Pharmaceuticals (AUPH) EBIT Margin (2019 - 2025)

Aurinia Pharmaceuticals (AUPH) has disclosed EBIT Margin for 7 consecutive years, with 3174.69% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBIT Margin fell 317190.0% year-over-year to 3174.69%, compared with a TTM value of 51.2% through Dec 2025, up 5320.0%, and an annual FY2025 reading of 2422.96%, down 242225.0% over the prior year.
  • EBIT Margin was 3174.69% for Q4 2025 at Aurinia Pharmaceuticals, down from 40.49% in the prior quarter.
  • Across five years, EBIT Margin topped out at 40.49% in Q3 2025 and bottomed at 5529.87% in Q1 2021.
  • Average EBIT Margin over 5 years is 522.46%, with a median of 52.39% recorded in 2023.
  • The sharpest move saw EBIT Margin soared 14557048bps in 2021, then tumbled -317190bps in 2025.
  • Year by year, EBIT Margin stood at 139.74% in 2021, then increased by 29bps to 98.82% in 2022, then skyrocketed by 33bps to 65.8% in 2023, then skyrocketed by 96bps to 2.79% in 2024, then crashed by -113776bps to 3174.69% in 2025.
  • Business Quant data shows EBIT Margin for AUPH at 3174.69% in Q4 2025, 40.49% in Q3 2025, and 28.69% in Q2 2025.